alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
IV 

109TH CONGRESS 

2D SESSION H. RES. 980 

Expressing condolences to the families, friends, and loved ones of the victims 

of the crash of Comair Flight 5191, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

SEPTEMBER 6, 2006 

Mr. CHANDLER (for himself, Mr. WHITFIELD, Mrs. NORTHUP, Mr. DAVIS of 

Kentucky, Mr. ROGERS of Kentucky, Mr. LEWIS of Kentucky, and Mr. 

SODREL) submitted the following resolution; which was referred to the 

Committee on Transportation and Infrastructure 

SEPTEMBER 6, 2006 

The Committee on Transportation and Infrastructure discharged; considered 

and agreed to 

RESOLUTION 

Expressing condolences to the families, friends, and loved 

ones of the victims of the crash of Comair Flight 5191, 

and for other purposes. 

Whereas the people of Kentucky, including the citizens of the 

6th Congressional District, have experienced a terrible 

tragedy with the loss of 49 lives in the crash of Comair 

Flight 5191 at Blue Grass Airport in Lexington, Kentucky, on August 27, 2006; 

Whereas many of the victims of the crash were residents of 

Kentucky, particularly of the small, close-knit town of 

Lexington and other surrounding communities; and 


jcorcoran on PRODPC62 with BILLS
2 

•HRES 980 ATH 

Whereas Federal, State, and local officials have cooperated 

not only at the crash site but throughout Kentucky and 

the Nation to respond to the emergency, investigate the 

accident, and provide assistance to families devastated by 

the loss of loved ones: Now, therefore, be it 

1 Resolved, That the House of Representatives— 

2 (1) expresses condolences to the families, 

3 friends, and loved ones of the victims of the crash 

4 of Comair Flight 5191; 

5 (2) honors the victims of the crash: Rebecca 

6 Adams, Christina Anderson, Lyle Anderson, Arnold 

7 Andrews, Anne Marie Bailey, Bobbie Benton, Jesse 

8 Clark Benton, Carole Bizzack, George Brunacini, 

9 Brian Byrd, Jeffrey Clay, Homer Combs, Diane 

10 Combs, Fenton Dawson, Thomas Fahey, Mike Fin11 ley, Clarence Wayne ‘‘C.W.’’ Fortney II, Wade 

12 Bartley ‘‘Bart’’ Frederick, Hollie Gilbert, Erik Har13 ris, Kelly Heyer, Jonathan Hooker, Scarlett Parsley 

14 Hooker, Priscilla Johnson, Tetsuya Kono, Nahoko 

15 Kono, Charles Lykins, Dan Mallory, Steve 

16 McElravy, Lynda McKee, Bobby Meaux, Leslie Mor17 ris II, Kaye Craig Morris, Cecile Moscoe, Judy Ann 

18 Rains, Michael Ryan, Mary Jane Silas, Pat Smith, 

19 Tim Snoddy, Marcie Thomason, Greg Threet, Randy 

20 Towles, Larry Turner, Victoria Washington, Jeff 


jcorcoran on PRODPC62 with BILLS
3 

•HRES 980 ATH 

1 Williams, Paige Winters, Bryan Woodward, JoAnn 

2 Wright, and Betty Young; 

3 (3) expresses sympathies to the people of Lex4 ington, the entire Commonwealth of Kentucky, and 

5 the Nation who grieve for the victims; 

6 (4) commends the heroic actions of the rescue 

7 workers at the crash site who retrieved copilot 

8 James M. Polehinke from the wreckage; and 

9 (5) commends the Federal, State, and local offi10 cials and the volunteers who worked together to re11 spond to the tragedy with courage, determination, 

12 and skill. 

Æ 


jcorcoran on PRODPC62 with BILLS
§ 556.425 Morantel. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of morantel tartrate is 10 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for N-methyl-1,3-propanediamine (marker residue) are: ( 1 ) *Cattle.* ( i ) Liver (target tissue): 0.7 ppm.
( ii ) Milk: Not required.
( 2 ) *Goats.* ( i ) Liver (target tissue): 0.7 ppm.
( ii ) Milk: Not required.
( c ) *Related conditions of use.* See §§ 520.1450a, 520.1450b, 520.1450c, and 558.360 of this chapter.
Fourth Court of Appeals

San Antonio, Texas

MEMORANDUM OPINION

No. 04-22-00353-CR

EX PARTE Andrez ZUNIGA-GUTIERREZ

From the County Court, Kinney County, Texas

Trial Court No. 12108CR

Honorable Roland Andrade, Judge Presiding

Opinion by: Lori I. Valenzuela, Justice

Sitting: Rebeca C. Martinez, Chief Justice

Luz Elena D. Chapa, Justice

Lori I. Valenzuela, Justice

Delivered and Filed: February 22, 2023

AFFIRMED

Appellant Andrez Zuniga-Gutierrez appeals the denial of his application for pretrial writ 

of habeas corpus. We affirm.

BACKGROUND

On January 9, 2022, appellant Andrez Zuniga-Gutierrez was arrested in Kinney County 

and charged with criminal trespass. He was appointed counsel and, on January 25, 2022, was 

released on bond. On April 14, 2022, the trial court issued a notice of setting for a pretrial hearing 

on April 22, 2022, and for a jury trial on May 9, 2022. The notice states: “Failure to appear may 

result in Bond Forfeiture and a Warrant of Arrest.”

Zuniga-Gutierrez alleges that after he was released on bond, the United States government 

removed him from this country. 
04-22-00353-CR

- 2 -

Through counsel, Zuniga-Gutierrez filed an application for a writ of habeas corpus, seeking 

dismissal of the charges against him for purported violations of the Fifth and Sixth Amendments 

to the United States Constitution and Articles I, sections 10 and 19, and V, section 1, of the Texas 

Constitution, alleging deprivations of due process and of his right to counsel.

1 He argued the State 

coordinated his removal with the federal government, leaving him unable to return to the United 

States for his trial setting.

The trial court denied habeas relief, and Zuniga-Gutierrez appealed. 

DISCUSSION

In Ex parte Dominguez Ortiz, we considered and rejected the argument that a noncitizen

habeas applicant, arrested on criminal trespass charges under Operation Lone Star, was entitled to 

dismissal of the charges against him after being released on bond and removed from the country. 

___ S.W.3d ___, No. 04-22-00260-CR, 2023 WL 1424651 (Tex. App.—San Antonio Feb. 1, 2023, 

no pet. h.) (en banc) (op. on reh’g). We concluded that the Fifth and Sixth Amendment claims the 

appellant asserted in that appeal were not cognizable by pretrial writ of habeas corpus. Id. at *7–

8. The claims Zuniga-Gutierrez asserts in this case are similar to those we addressed in Dominguez 

Ortiz. For the reasons described in that opinion, we affirm the trial court’s order denying habeas 

relief.

Lori I. Valenzuela, Justice

DO NOT PUBLISH

1 Because Zuniga-Gutierrez did not separately argue his state and federal constitutional claims or argue that the Texas 

Constitution provides different or broader protections than the United States Constitution, we address appellant’s 

claims solely on federal constitutional grounds. See Bohannan v. State, 546 S.W.3d 166, 179 n.7 (Tex. Crim. App. 

2017); Jackson v. State, 992 S.W.2d 469, 475 n.8 (Tex. Crim. App. 1999).
§ 522.1222 Ketamine. ( a ) *Specifications.* Each milliliter contains ketamine hydrochloride equivalent to 100 milligrams (mg) ketamine base activity.
( b ) *Sponsors.* See Nos. 00010, 017033, 054771, 058198, 059399, and 069043 in § 510.600(c) of this chapter.
( c ) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( d ) *Conditions of use* — ( 1 ) *Cats* — ( i ) *Amount.* 5 to 15 mg/pound body weight intramuscularly, depending on the effect desired.
( ii ) *Indications for use.* For restraint or as the sole anesthetic agent in diagnostic or minor, brief surgical procedures that do not require skeletal muscle relaxation.
( 2 ) *Subhuman primates* — ( i ) *Amount.* 3 to 15 mg/kilogram body weight intramuscularly, depending upon the species, general condition, and age of the subject.
( ii ) *Indications for use.* For restraint.
[67 FR 17283, Apr. 10, 2002, as amended at 73 FR 8192, Feb. 13, 2008. Redesignated at 79 FR 16191, Mar. 25, 2014, as amended at 80 FR 13229, Mar. 13, 2015; 83 FR 48946, Sept. 28, 2018; 86 FR 14820, Mar. 19, 2021; 88 FR 27699, May 3, 2023; 88 FR 55564, Aug. 16, 2023]
§ 516.1780 Pimobendan. ( a ) Specifications . Each chewable tablet contains 1.25, 2.5, 5, or 10 milligrams (mg) pimobendan.
( b ) Sponsor . See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer orally at a total daily dose of 0.23 mg per pound (0.5 mg per kilogram) body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into two portions administered approximately 12 hours apart.
( 2 ) *Indications for use in dogs.* For the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease (2019 ACVIM Consensus Statement). Stage B2 preclinical myxomatous mitral valve disease (MMVD) refers to dogs with asymptomatic MMVD that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.
[87 FR 76421, Dec. 14, 2022]
**EXHIBIT
      32.1**




**CERTIFICATION
      PURSUANT TO 18 U.S.C. SECTION 1350**


**AS
      ADOPTED PURSUANT TO**


**SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002**




In
      connection with the Quarterly Report of Central Wireless, Inc. (the “Company”)
      on Form 10-QSB for the quarter ended September 30, 2005 as filed with the
      Securities and Exchange Commission on the date hereof (the “Report”), the
      undersigned, in the capacities and on the dates indicated below, hereby
      certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
      906
      of the Sarbanes-Oxley Act of 2002, that to his knowledge:




1.
      The
      Report fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and




2.
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operation of the Company.




Date:
                  January 19, 2007
              By:
              /s/ *Kenneth
                W. Brand*Kenneth
                    W. Brand
                  Chief
                    Executive Officer


A
      signed
      original of this written statement required by Section 906, or other document
      authentications, acknowledging, or otherwise adopting the signature that appears
      in typed form within the electronic version of this written statement required
      by Section 906, has been provided to Central Wireless, Inc. and will be retained
      by Central Wireless, Inc. and furnished to the Securities and Exchange
      Commission or its staff upon request.
#### § 601.40 Scope.

This subpart applies to certain biological products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit to patients over existing treatments (e.g., ability to treat patients unresponsive to, or intolerant of, available therapy, or improved patient response over available therapy).
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States

              																								United States. Congress. Joint Economic Committee, 1956-					 and 	Eighty-Sixth Congress, 1959-1961.						"Study Paper Nos. 4 and 5 : Analysis of the Rising Costs of Public Education and Trends in the Supply and Demand of Medical Care" in *Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States*			(November 10, 1959).						https://fraser.stlouisfed.org/title/1244/item/3644, accessed on September 23, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
§ 26.81 Final provisions. ( a ) The sectoral annexes referred to in § 26.80(a), as well as any new sectoral annexes added pursuant to § 26.80(b), shall form an integral part of the “Agreement on Mutual Recognition Between the United States of America and the European Community,” from which this part is derived.
( b ) For a given product or sector, the provisions contained in subparts A and B of this part shall apply in the first place, and the provisions of subpart C of this part in addition to those provisions. In the case of any inconsistency between the provisions of subpart A or B of this part and subpart C of this part, subpart A or B shall prevail, to the extent of that inconsistency.
( c ) The agreement from which this part is derived shall not affect the rights and obligations of the parties under any other international agreement.
( d ) In the case of subpart B of this part, the parties shall review the status of such subpart at the end of 3 years from the date described in § 26.80(a).
#### § 573.220 Feed-grade biuret.

The food additive feed grade biuret may be safely used in ruminant feed in accordance with the following prescribed conditions:

(a) The food additive is the product resulting from the controlled pyrolysis of urea conforming to the following specifications:

| | Percent |
| --- | --- |
| Biuret | 55 minimum. |
| Urea | 15 maximum. |
| Cyanuric acid and triuret | 30 maximum. |
| Mineral oil | 0.5 maximum. |
| Total nitrogen (equivalent to 218.75 pct crude protein) | 35 minimum. |

(b) It is used in ruminant feeds as a source of nonprotein nitrogen.

(c) To assure safe use of the additive:

(1) The label and labeling of the additive and that of any feed additive supplement, feed additive concentrate, feed additive premix, or complete feed prepared therefrom shall contain, in addition to other information required by the act, the following:

(i) The name of the additive.

(ii) The maximum percentage of equivalent crude protein from nonprotein nitrogen.

(2) The label shall recommend that the diet be balanced to provide adequate nutrients when equivalent crude protein from all forms of nonprotein nitrogen exceed one-third of the total crude protein in the total daily ration.

[41 FR 38652, Sept. 10, 1976, as amended at 68 FR 27904, May 22, 2003]
§ 582.3616 Potassium bisulfite. ( a ) *Product.* Potassium bisulfite.
( b ) [Reserved]
( c ) *Limitations, restrictions, or explanation.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice, except that it is not used in meats or in food recognized as source of vitamin B1.
#### § 606.65 Supplies and reagents.

All supplies and reagents used in the collection, processing, compatibility testing, storage and distribution of blood and blood components shall be stored in a safe, sanitary and orderly manner.

(a) All surfaces coming in contact with blood and blood components intended for transfusion shall be sterile, pyrogen-free, and shall not interact with the product in such a manner as to have an adverse effect upon the safety, purity, potency or effectiveness of the product. All final containers and closures for blood and blood components not intended for transfusion shall be clean and free of surface solids and other contaminants.

(b) Each blood collecting container and its satellite container(s), if any, shall be examined visually for damage or evidence of contamination prior to its use and immediately after filling. Such examination shall include inspection for breakage of seals, when indicated, and abnormal discoloration. Where any defect is observed, the container shall not be used, or, if detected after filling, shall be properly discarded.

(c) Representative samples of each lot of the following reagents or solutions shall be tested on a regularly scheduled basis by methods described in the Standard Operating Procedures Manual to determine their capacity to perform as required:

| Reagent or solution | Frequency of testing |
| --- | --- |
| Anti-human globulin | Each day of use. |
| Blood grouping reagents | Do. |
| Lectins | Do. |
| Antibody screening and reverse grouping cells | Do. |
| Hepatitis test reagents | Each run. |
| Syphilis serology reagents | Do. |
| Enzymes | Each day of use. |

(d) Supplies and reagents that do not bear an expiration date shall be stored in such a manner that the oldest is used first.

(e) Supplies and reagents shall be used in a manner consistent with instructions provided by the manufacturer.

(f) Items that are required to be sterile and come into contact with blood should be disposable whenever possible.

[40 FR 53532, Nov. 18, 1975, as amended at 59 FR 23636, May 6, 1994]
# C_2014303EN.01002101.xml

| 8.9.2014 | EN | Official Journal of the European Union | C 303/21 |
| --- | --- | --- | --- |

8.9.2014

EN

Official Journal of the European Union

C 303/21

---

Request for a preliminary ruling from the Oberster Gerichtshof (Austria) lodged on 13 June 2014 — Gerhart Hiebler v Walter Schlagbauer

(Case C-293/14)

2014/C 303/27

Language of the case: German

Referring court

Referring court

Oberster Gerichtshof

Parties to the main proceedings

Parties to the main proceedings

Applicant: Gerhart Hiebler

Applicant:

Defendant: Walter Schlagbauer

Defendant:

Questions referred

Questions referred

| 1. | In accordance with Article 2(2)(i) of Directive 2006/123/EC of the European Parliament and of the Council of 12 December 2006 on services in the internal market, (1) is the entire commercial activity of a chimney sweep excluded from the scope of that directive because chimney sweeps also perform tasks in the field of fire safety regulation (fire safety inspections, expert reports in the course of building approval procedures etc.)?
  If Question 1 is answered in the negative: |
| --- | --- |

1.

In accordance with Article 2(2)(i) of Directive 2006/123/EC of the European Parliament and of the Council of 12 December 2006 on services in the internal market, (1) is the entire commercial activity of a chimney sweep excluded from the scope of that directive because chimney sweeps also perform tasks in the field of fire safety regulation (fire safety inspections, expert reports in the course of building approval procedures etc.)?

1

If Question 1 is answered in the negative:

| 2. | Is a scheme, provided for in national law, under which the licence to trade as a chimney sweep is limited to a particular ‘Kehrgebiet’ (sweeping area) compatible with Article 10(4) and Article 15(1), (2)(a) and (3) of Directive 2006/123/EC? |
| --- | --- |

2.

Is a scheme, provided for in national law, under which the licence to trade as a chimney sweep is limited to a particular ‘Kehrgebiet’ (sweeping area) compatible with Article 10(4) and Article 15(1), (2)(a) and (3) of Directive 2006/123/EC?

---

(1)  OJ 2006 L 376, p. 36.

1

---
NOTE: This order is nonprecedential.

United States Court of Appeals 

for the Federal Circuit ______________________

CADDO SYSTEMS, INC., 511 TECHNOLOGIES, 

INC., 

Plaintiffs-Appellees

v.

MICROCHIP TECHNOLOGY, INC., 

Defendant-Appellant

______________________

2022-2043

______________________

Appeal from the United States District Court for the 

Western District of Texas in No. 6:20-cv-00245-ADA, Judge 

Alan D. Albright.

______________________

O R D E R

The parties having so agreed, it is ordered that:

(1) The proceeding is DISMISSED under Fed. R. App. 

P. 42 (b).

Case: 22-2043 Document: 7 Page: 1 Filed: 08/04/2022
2 CADDO SYSTEMS, INC. V. MICROCHIP TECHNOLOGY, INC.

(2) Each side shall bear their own costs.

FOR THE COURT

August 4, 2022

Date /s/ Peter R. Marksteiner

Peter R. Marksteiner 

Clerk of Court

ISSUED AS A MANDATE: August 4, 2022

Case: 22-2043 Document: 7 Page: 2 Filed: 08/04/2022
§ 573.625 Menadione nicotinamide bisulfite. The food additive may be safely used as follows: ( a ) The additive is 1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-2-naphthalene sulfonic acid with 3-pyridine carboxylic acid amine (CAS No. 73581-79-0).
( b ) The additive is used or intended for use as a nutritional supplement for both the prevention of vitamin K deficiency and as a source of supplemental niacin as follows: ( 1 ) In chicken and turkey feeds at a level not to exceed 2 grams per ton of complete feed.
( 2 ) In growing and finishing swine feeds at a level not to exceed 10 grams per ton of complete feed.
( c ) To assure safe use, the label and labeling of the additive shall bear adequate directions for use.
[64 FR 46840, Aug. 27, 1999]
§ 26.38 Other transition period activities. ( a ) During the transition period, the parties will jointly determine the necessary information which must be present in quality system and product evaluation reports.
( b ) The parties will jointly develop a notification and alert system to be used in case of defects, recalls, and other problems concerning product quality that could necessitate additional actions (e.g., inspections by the parties of the importing country) or suspension of the distribution of the product.